Assessment of a combined strategy of seasonal malaria chemoprevention and supplementation with vitamin A, zinc and Plumpy'Doz™ to prevent malaria and malnutrition in children under 5 years old in Burkina Faso: a randomized open-label trial (SMC-NUT).


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
24 May 2021
Historique:
received: 24 09 2020
accepted: 08 05 2021
entrez: 25 5 2021
pubmed: 26 5 2021
medline: 22 6 2021
Statut: epublish

Résumé

Malaria and malnutrition represent major public health concerns worldwide especially in Sub-Sahara Africa. Despite implementation of seasonal malaria chemoprophylaxis (SMC), an intervention aimed at reducing malaria incidence among children aged 3-59 months, the burden of malaria and associated mortality among children below age 5 years remains high in Burkina Faso. Malnutrition, in particular micronutrient deficiency, appears to be one of the potential factors that can negatively affect the effectiveness of SMC. Treating micronutrient deficiencies is known to reduce the incidence of malaria in highly prevalent malaria zone such as rural settings. Therefore, we hypothesized that a combined strategy of SMC together with a daily oral nutrients supplement will enhance the immune response and decrease the incidence of malaria and malnutrition among children under SMC coverage. Children (6-59 months) under SMC coverage receiving vitamin A supplementation will be randomly assigned to one of the three study arms (a) SMC + vitamin A alone, (b) SMC + vitamin A + zinc, or (c) SMC + vitamin A + Plumpy'Doz™ using 1:1:1 allocation ratio. After each SMC monthly distribution, children will be visited at home to confirm drug administration and followed-up for 1 year. Anthropometric indicators will be recorded at each visit and blood samples will be collected for microscopy slides, haemoglobin measurement, and spotted onto filter paper for further PCR analyses. The primary outcome measure is the incidence of malaria in each arm. Secondary outcome measures will include mid-upper arm circumference and weight gain from baseline measurements, coverage and compliance to SMC, occurrence of adverse events (AEs), and prevalence of molecular markers of antimalarial resistance comprising Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps. This study will demonstrate an integrated strategy of malaria and malnutrition programmes in order to mutualize resources for best impact. By relying on existing strategies, the policy implementation of this joint intervention will be scalable at country and regional levels. ClinicalTrials.gov NCT04238845 . Registered on 23 January 2020 https://clinicaltrials.gov/ct2/show/NCT04238845.

Sections du résumé

BACKGROUND BACKGROUND
Malaria and malnutrition represent major public health concerns worldwide especially in Sub-Sahara Africa. Despite implementation of seasonal malaria chemoprophylaxis (SMC), an intervention aimed at reducing malaria incidence among children aged 3-59 months, the burden of malaria and associated mortality among children below age 5 years remains high in Burkina Faso. Malnutrition, in particular micronutrient deficiency, appears to be one of the potential factors that can negatively affect the effectiveness of SMC. Treating micronutrient deficiencies is known to reduce the incidence of malaria in highly prevalent malaria zone such as rural settings. Therefore, we hypothesized that a combined strategy of SMC together with a daily oral nutrients supplement will enhance the immune response and decrease the incidence of malaria and malnutrition among children under SMC coverage.
METHODS METHODS
Children (6-59 months) under SMC coverage receiving vitamin A supplementation will be randomly assigned to one of the three study arms (a) SMC + vitamin A alone, (b) SMC + vitamin A + zinc, or (c) SMC + vitamin A + Plumpy'Doz™ using 1:1:1 allocation ratio. After each SMC monthly distribution, children will be visited at home to confirm drug administration and followed-up for 1 year. Anthropometric indicators will be recorded at each visit and blood samples will be collected for microscopy slides, haemoglobin measurement, and spotted onto filter paper for further PCR analyses. The primary outcome measure is the incidence of malaria in each arm. Secondary outcome measures will include mid-upper arm circumference and weight gain from baseline measurements, coverage and compliance to SMC, occurrence of adverse events (AEs), and prevalence of molecular markers of antimalarial resistance comprising Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps.
DISCUSSION CONCLUSIONS
This study will demonstrate an integrated strategy of malaria and malnutrition programmes in order to mutualize resources for best impact. By relying on existing strategies, the policy implementation of this joint intervention will be scalable at country and regional levels.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT04238845 . Registered on 23 January 2020 https://clinicaltrials.gov/ct2/show/NCT04238845.

Identifiants

pubmed: 34030705
doi: 10.1186/s13063-021-05320-7
pii: 10.1186/s13063-021-05320-7
pmc: PMC8142067
doi:

Substances chimiques

Antimalarials 0
Pharmaceutical Preparations 0
Vitamin A 11103-57-4
Zinc J41CSQ7QDS

Banques de données

ClinicalTrials.gov
['NCT04238845']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

360

Subventions

Organisme : European & Developing Countries Clinical Trials Partnership (EDCTP)
ID : TMA2018CDF-2365

Références

Nutr J. 2008 Jan 31;7:7
pubmed: 18237394
PLoS One. 2013 May 29;8(5):e64636
pubmed: 23734210
PLoS One. 2009;4(5):e5455
pubmed: 19421316
Malar J. 2017 Oct 27;16(1):433
pubmed: 29078773
BMC Public Health. 2019 Feb 28;19(1):249
pubmed: 30819132
Nutr J. 2013 Sep 23;12:131
pubmed: 24330422
Lancet. 2006 Feb 25;367(9511):659-67
pubmed: 16503464
Malar J. 2007 Sep 06;6:121
pubmed: 17822535
PLoS Med. 2011 Feb 01;8(2):e1000408
pubmed: 21304925
Int J Epidemiol. 2012 Oct;41(5):1293-301
pubmed: 23045201
Am J Clin Nutr. 2020 Jan 1;111(1):207-218
pubmed: 31697329
Lancet. 2013 Aug 3;382(9890):427-451
pubmed: 23746772
Am J Trop Med Hyg. 2018 Feb;98(2):524-533
pubmed: 29260654

Auteurs

Paul Sondo (P)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso. paulsondo@yahoo.fr.

Marc Christian Tahita (MC)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Toussaint Rouamba (T)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Karim Derra (K)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Bérenger Kaboré (B)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Cheick Saïd Compaoré (CS)

National Malaria Control Program, Ministry of Health, Ouagadougou, Burkina Faso.

Florence Ouédraogo (F)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Eli Rouamba (E)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Hamidou Ilboudo (H)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Estelle Aïssa Bambara (EA)

Nutrition Direction, Ministry of Health, Ouagadougou, Burkina Faso.

Macaire Nana (M)

Health District of Nanoro, Ministry of Health, Nanoro, Burkina Faso.

Edmond Yabré Sawadogo (EY)

Health District of Nanoro, Ministry of Health, Nanoro, Burkina Faso.

Hermann Sorgho (H)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Athanase Mwinessobaonfou Somé (AM)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Innocent Valéa (I)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Prabin Dahal (P)

Infectious Diseases Data Observatory (IDDO), University of Oxford, Oxford, UK.

Maminata Traoré/Coulibaly (M)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Halidou Tinto (H)

Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH